FDA approves over the counter use of
Next Choice™ by Watson Pharmaceuticals
The Food and Drug Administration (FDA) announced on June 24, 2009 that it has approved levonorgestrel tablets, a progestin, for use with a prescription. On August 28, 2009 the FDA approved the drug for over-the-counter use.
Manufactured by Watson Pharmaceuticals through its subsidiary, Watson Laboratories, Inc., the drug will be sold under the name Next Choice™. The over-the-counter use is available for women ages 18 and above.
Often called the "morning after pill" the drug acts to prevent ovulation or fertilization. It can effect post fertilization but is different from a pharmaceutical abortion which is intended to act after implantation.
This drug is intended for occasional use either after unprotected sex or if a primary method of birth control fails. Because the progestin only pill acts before implantation it is medically and legally considered to be a form of contraception. It should be noted that the drug does not prevent sexually transmitted diseases, including HIV.
Because there is some evidence that this drug may act after fertilization, many people believe that it should be considered an abortifacient, a substance that induces abortion.
Another morning after pill known as Plan B was approved by the FDA in July 1999.
Calling the drug a “morning after pill” is inaccurate. The drug is most effective when used shortly before intercourse but may be used up to 72 hours later. The World Health Organization (WHO) has published findings that this drug may be used up to 5 days and still prevent conception.
FDA requires that the drug be sold only at licensed pharmacies and clinics. It must be kept behind the counter so that pharmacy staff can check a buyer’s proof of age. Use by any woman under age 18 must be by prescription.
Follow health and insurance issues with this Examiner by clicking on "SUBSCRIBE" at the top of this article. Comments are welcome and appreciated. Rudeness is neither welcome nor appreciated.
Comments